Mechanism of Orcinol Glucoside in Treatment of Osteoporosis： An Exploration Based on Network Pharmacology and <italic style="font-style: italic">in Vitro</italic> Validation

Xia LIU; Ming-chun HUANG; Xiao-qiong ZHANG; Jie LI; Mei ZHANG

doi:10.13422/j.cnki.syfjx.20211519

您当前的位置：

首页 >

文章列表页 >

Mechanism of Orcinol Glucoside in Treatment of Osteoporosis： An Exploration Based on Network Pharmacology and in Vitro Validation

更新时间：2022-01-04

- Mechanism of Orcinol Glucoside in Treatment of Osteoporosis： An Exploration Based on Network Pharmacology and in Vitro Validation
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 28, Issue 1, Pages: 197-203(2022)
- 作者机构：
  
  1.成都中医药大学药学院，省部共建西南特色中药资源国家重点实验室，成都 611137
  2.重庆市中医院，重庆 400021
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20211519
  CLC： R285;R289;R22;R2-031;R33
- Received：15 June 2021，
  
  Published Online：04 November 2021，
  
  Published：05 January 2022
- 稿件说明：
移动端阅览
刘霞,黄明春,张小琼等.基于网络药理学和体外实验研究苔黑酚葡萄糖苷治疗骨质疏松的分子机制[J].中国实验方剂学杂志,2022,28(01):197-203.

LIU Xia,HUANG Ming-chun,ZHANG Xiao-qiong,et al.Mechanism of Orcinol Glucoside in Treatment of Osteoporosis： An Exploration Based on Network Pharmacology and in Vitro Validation[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(01):197-203.
刘霞,黄明春,张小琼等.基于网络药理学和体外实验研究苔黑酚葡萄糖苷治疗骨质疏松的分子机制[J].中国实验方剂学杂志,2022,28(01):197-203. DOI： 10.13422/j.cnki.syfjx.20211519.

LIU Xia,HUANG Ming-chun,ZHANG Xiao-qiong,et al.Mechanism of Orcinol Glucoside in Treatment of Osteoporosis： An Exploration Based on Network Pharmacology and in Vitro Validation[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(01):197-203. DOI： 10.13422/j.cnki.syfjx.20211519.

摘要

目的

基于网络药理学预测苔黑酚葡萄糖苷（OG）治疗骨质疏松的作用靶点及相关信号通路，应用分子对接和体外实验验证，从而揭示其潜在作用机制。

方法

通过Similarity ensemble approach（SEA），SwissTargetPrediction数据库获取OG药物靶点；通过疾病相关的基因与突变位点数据库（DisGeNET），GeneCards数据库获取疾病靶点，交叉分析筛选出OG与骨质疏松共同作用靶点。利用STRING构建蛋白质-蛋白质相互作用（PPI）网络，随后利用Cytoscape 3.7.2软件中的CytoNCA插件进行拓扑分析筛选出核心靶点。其次，通过g：Profiler基因注释网站对所得共同靶点进行基因本体（GO）与京都基因与基因组百科全书（KEGG）富集分析。最后，AutoDock Vina软件用来进行分子对接以及体外细胞实验验证OG的抗骨质疏松作用。

结果

OG与骨质疏松的相关靶点73个，其中关键靶点14个。GO和KEGG功能富集分析结果表明，OG治疗骨质疏松涉及259个细胞生物学过程，主要包括有机氮化合物的代谢、细胞群增殖、蛋白质代谢过程、应激反应的调节、化学反应等。其作用机制可能与糖基化终末产物/糖基化终末产物受体（AGE/RAGE），白细胞介素-17（IL-17），磷脂酰肌醇3-激酶/蛋白激酶B（PI3K/Akt）等信号通路相关。分子对接提示OG与关键靶点细胞周期蛋白D

（CCND1或Cyclin D

），周期蛋白依赖性激酶4（CDK4）的结合能最低且相近。流式细胞仪检测结果显示，与正常组比较，OG组G

期细胞比例下降（

0.01），S期细胞比例明显增加（

0.01）；蛋白免疫印迹法（Western blot）结果显示，与正常组比较，OG能上调Cyclin D

，CDK4蛋白的表达（

0.05，

0.01）。

结论

OG治疗骨质疏松具有多靶点-多通路的特点，作用机制可能通过上调细胞周期关键蛋白Cyclin D

，CDK4的表达改变细胞周期，从而促进细胞增殖。

Abstract

Objective

To predict the therapeutic targets and related signaling pathways of orcinol glucoside （OG） in the treatment of osteoporosis by network pharmacology， and further clarify its mechanisms based on molecular docking and

in vitro

cell model.

Method

The pharmacological targets of OG were obtained from Similarity ensemble approach （SEA） and SwissTargetPrediction， and the targets related to osteoporosis from DisGeNET and GeneCards. The cross-analysis was conducted to screen the common targets between OG and osteoporosis. STRING was used to construct the protein-protein interaction （PPI） network， followed by topology analysis using CytoNCA plug-in of Cytoscape 3.7.2 to screen out the core targets. The obtained common targets were subjected to gene ontology （GO） and Kyoto encyclopedia of genes and genomes （KEGG） analysis by g：Profiler. AutoDock Vina was utilized for molecular docking， and the

in vitro

cell experiments were then carried out for verifying the mechanism of OG in treating osteoporosis.

Result

A total of 73 targets related to OG and osteoporosis were harvested，among which 14 were proved to be key targets by topological analysis. GO and KEGG functional enrichment analysis yielded 259 cell biological processes， mainly involving organonitrogen compound metabolic process， cell population proliferation， protein metabolic process， regulation of response to stress， and response to chemicals. Its mechanism of action might be related to advanced glycation end-product （AGE）-AGE receptor （RAGE） signaling pathway， interleukin-17 （IL-17） signaling pathway， and phosphatidylinositol 3-kinase （PI3K）/protein kinase B （Akt） signaling pathway. Molecular docking indicated that the binding energies of OG to Cyclin D

（CCND1） and cyclin-dependent kinase 4 （CDK4） were the lowest and similar. The results of flow cytometry showed that compared with the normal group， OG group exhibited decreased proportion of cells in G

phase （

0.01） and decreased proportion of cells in S phase （

0.01）. As demonstrated by Western blot， compared with the normal group， OG up-regulated the protein expression levels of Cyclin D

and CDK4 （

0.05，

0.01）.

Conclusion

OG alleviates osteoporosis via multiple targets and multiple pathways. It may exert the therapeutic effects by increasing Cyclin D1 and CDK4 protein expression to change cell cycle and promote cell proliferation.

关键词

Keywords

references

BLACK D M ， ROSEN C J . Postmenopausal osteoporosis ［J］. N Engl J Med ， 2016 ， 374 （ 3 ）： 254 - 262 .

中华医学会骨质疏松和骨矿盐疾病分会 . 中国骨质疏松症流行病学调查及“健康骨骼”专项行动结果发布［J］. 中华骨质疏松和骨矿盐疾病杂志， 2019 ， 12 （ 4 ）： 317 - 318 .

叶丹 . 骨质疏松药物治疗的研究进展［J］. 牡丹江医学院学报， 2021 ， 42 （ 1 ）： 148 - 151 .

钟建春，谢兴文，李鼎鹏，等 . 补肾方药治疗骨质疏松的研究进展［J］. 中国中医骨伤科杂志， 2021 ， 29 （ 3 ）： 85 - 88 .

张骞予，杨鸫祥，楼家晖 . 补肾中药诱导骨髓间充质干细胞增殖分化防治骨质疏松的研究进展［J］. 中华中医药学刊， 2020 ， 38 （ 3 ）： 193 - 195 .

周芳，姚萌，吴倩，等 . 仙茅的化学成分和药理活性研究进展［J］. 中草药， 2020 ， 51 （ 8 ）： 2238 - 2247 .

强明敏，尹佳，刘会会，等 . 苔黑酚葡萄糖苷药代动力学及药理活性研究进展［J］. 辽宁中医药大学学报， 2021 ， doi： 21.1543.R.20210514.1107.016 http://dx.doi.org/21.1543.R.20210514.1107.016 .

ZHOU X Y ， LIU Z Z ， HUANG B ， et al . Orcinol glucoside facilitates the shift of MSC fate to osteoblast and prevents adipogenesis via Wnt/ β -catenin signaling pathway ［J］. Drug Des Devel Ther ， 2019 ， 13 ： 2703 - 2713 .

LI J ， HUANG Y Q ， ZHAO S ， et al . Based on network pharmacology to explore the molecular mechanisms of astragalus membranaceus for treating T2 diabetes mellitus ［J］. Ann Transl Med， 2019 ， 7 （ 22 ）： 633 - 633 .

ORRIS G M ， HUEY R ， LINDSTROM W ， et al . AutoDock4 and AutoDockTools4：automated docking with selective receptor flexibility ［J］. J Comput Chem ， 2009 ， 30 （ 16 ）： 2785 - 2791 .

ZHAO H Y ， ZHAO N ， ZHENG P ， et al . Prevention and treatment of osteoporosis using Chinese medicinal plants：special emphasis on mechanisms of immune modulation ［J］. J Immunol Res ， 2018 ，2018（ 4 ）： 1 - 11 .

梁伟乔，钟诚，李宇明 . 骨质疏松症的中医病因病机认识与治疗进展［J］. 中国骨质疏松杂志， 2020 ， 26 （ 1 ）： 135 - 139 .

刘谊民，许婷，张黄琴，等 . 基于谱效关系和网络药理学的淫羊藿抗骨质疏松物质基础及作用机制探索［J］. 中国实验方剂学杂志， 2021 ， doi： 10.13422/j.cnki.syfjx.20210917 http://dx.doi.org/10.13422/j.cnki.syfjx.20210917 .

门志涛，徐敏，黄承军，等 . 基于网络药理学研究杜仲治疗骨质疏松性骨折的作用机制［J］. 中国骨质疏松杂志， 2021 ， 27 （ 5 ）： 721 - 726 .

岳志军，姜自伟，李紫阁，等 . 基于网络药理学和分子对接探讨补肾活血汤“从虚从瘀”治疗骨质疏松症的分子机制［J］. 中国骨质疏松杂志， 2021 ， 27 （ 4 ）： 542 - 548，584 .

谭张奎，周广文，张妍，等 . 补肾化痰方对去势骨质疏松模型大鼠Th17/Treg平衡机制的影响［J］. 中国实验方剂学杂志， 2021 ， 27 （ 5 ）： 33 - 40 .

童宇茹，张逸风，沈思雨，等 . 中药活性成分“合成生物学”创造与新药发现——高伟教授［J］. 首都医科大学学报， 2020 ， 41 （ 5 ）： 783 - 787 .

WANG N ， XU P ， WANG X ， et al . Integrated pathological cell fishing and network pharmacology approach to investigate main active components of Er-Xian decotion for treating osteoporosis ［J］. J Ethnopharmacol ， 2019 ， 241 ： 111977 .

史东梅，董明，陆颖，等 . PI3K/Akt信号通路与骨破坏：问题与机制［J］. 中国组织工程研究， 2020 ， 24 （ 23 ）： 3716 - 3722 .

郭晨旭，刘静波，谢强，等 . 白术内酯Ⅰ通过调低Cyclin D1/CDK4抑制胃癌细胞SGC-7901的增殖及机制［J］. 蚌埠医学院学报， 2020 ， 45 （ 4 ）： 456 - 460 .

TCHAKARSKA G ， SOLA B . The double dealing of cyclin D1 ［J］. Cell Cycle ， 2020 ， 19 （ 2 ）： 163 - 178 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism of Polygonati Rhizoma on Treating Osteoporosis Based on Network Pharmacology and Preliminary Verification

Mahoniae Caulis Alkaloids Ameliorate Depression by Regulating Synaptic Plasticity via cAMP Pathway

Analysis of Potential Active Components and Molecular Mechanism of Baoxin Granules Regulating Ferroptosis in Treatment of Heart Failure

Effect and Mechanism of Angelicae Sinensis Radix-Polygonati Rhizoma Herb Pair in Treatment of Simple Obesity

Screening of Anti-breast Cancer Active Ingredients in Famous Classical Formula Yanghetang

Related Author

Jia-le MAI

Jian-liang LI

Jia-cong XIAO

Du LIANG

Hai-bin WANG

HE Junhui

JIA Chunlian

LAI Kedao

Related Institution

Guangzhou University of Chinese Medicine

Guangzhou Orthopedic Hospital，Guanghzou

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

Key Laboratory of Chemistry and Engineering of Forest Products， National Ethnic Affairs Commission， Guangxi Key Laboratory of Chemistry and Engineering of Forest Products/Guangxi Collaborative Innovation Center for Chemistry and Engineering of Forest Products， School of Chemistry and Chemical Engineering， Guangxi Minzu University

Guangxi Key Laboratory of Chinese Medicine Quality Standard， Guangxi Institute of Chinese Medicine and Pharmaceutical Science

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Mechanism of Orcinol Glucoside in Treatment of Osteoporosis： An Exploration Based on Network Pharmacology and in Vitro Validation

DOI：10.13422/j.cnki.syfjx.20211519

摘要

Abstract

关键词

Keywords

references